AVTX

SEC source: 0001247024-26-000004 · form4-06042026_040607.xml · derivative · entry 1

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

Underlying: Common Stock · 20,100 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

SEC source: 0001677036-26-000004 · form4-06042026_040609.xml · derivative · entry 1

Lind Kevin Robert · CIK 0001677036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

Underlying: Common Stock · 20,100 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

SEC source: 0001707797-26-000008 · form4-06042026_040601.xml · derivative · entry 1

Jain Rita · CIK 0001707797 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

Underlying: Common Stock · 20,100 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.

SEC source: 0001918845-26-000016 · form4-06012026_040618.xml · derivative · entry 3

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,321

Underlying: Common Stock · 679 shares

Expires 2035-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000016 · form4-06012026_040618.xml · nonDerivative · entry 2

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,122

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000016 · form4-06012026_040618.xml · nonDerivative · entry 1

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,801

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0002047607-26-000004 · form4-05262026_040508.xml · nonDerivative · entry 1

Riley Jennifer · CIK 0002047607 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,855

F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001810417-26-000014 · form4-05262026_040507.xml · nonDerivative · entry 1

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,323

F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001677896-26-000006 · form4-05262026_040505.xml · nonDerivative · entry 1

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,934

F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001918845-26-000014 · form4-05262026_040503.xml · nonDerivative · entry 1

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,122

F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001586785-26-000006 · form4-05262026_040501.xml · nonDerivative · entry 1

NEIL GARRY ARTHUR · CIK 0001586785 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,314

F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001918845-26-000012 · form4-05192026_040503.xml · derivative · entry 3

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,625

Underlying: Common Stock · 3,000 shares

Expires 2034-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F2 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000012 · form4-05192026_040503.xml · nonDerivative · entry 2

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,622

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000012 · form4-05192026_040503.xml · nonDerivative · entry 1

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001810417-26-000012 · form4-05112026_040503.xml · derivative · entry 3

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,094

Underlying: Common Stock · 18,606 shares

Expires 2034-08-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F3 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001810417-26-000012 · form4-05112026_040503.xml · nonDerivative · entry 2

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F2 · price: The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000012 · form4-05112026_040503.xml · nonDerivative · entry 1

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · derivative · entry 7

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,000

Underlying: Common Stock · 47,000 shares

Expires 2035-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 6

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F6 · price: The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 5

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,323

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F5 · price: The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 4

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,542

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 3

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,242

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 2

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,589

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F2 · price: The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 1

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,423

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · derivative · entry 9

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,437

Underlying: Common Stock · 12,563 shares

Expires 2035-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · derivative · entry 8

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 62,500 shares

Expires 2034-06-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F6 · derivative.exercise_date: Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 7

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,634

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 6

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,034

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F5 · price: The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 5

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,287

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 4

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,126

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 3

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,322

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F2 · price: The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 2

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

SEC source: 0001677896-26-000004 · form4-05072026_080504.xml · nonDerivative · entry 1

VARKI PAUL · CIK 0001677896 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 14

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,000

Underlying: Common Stock · 28,650 shares

Expires 2035-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 13

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,625

Underlying: Common Stock · 77,905 shares

Expires 2034-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F6 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 10

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,622

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 9

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,680

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F5 · price: The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 8

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,695

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 7

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,639

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 6

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,639

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F2 · price: The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 5

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,177

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 4

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001789335-26-000006 · form4-05072026_080503.xml · nonDerivative · entry 1

Chan Mitchell · CIK 0001789335 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,166

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 12

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,650

Underlying: Common Stock · 679 shares

Expires 2035-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · derivative · entry 11

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,530

Underlying: Common Stock · 1,000 shares

Expires 2034-07-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

F6 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 3

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,622

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 2

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001918845-26-000010 · form4-05072026_080500.xml · nonDerivative · entry 1

Doyle Mittie · CIK 0001918845 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

SEC source: 0001810417-26-000008 · form4-05012026_080546.xml · nonDerivative · entry 2

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 423

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F3 · price: The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001810417-26-000008 · form4-05012026_080546.xml · nonDerivative · entry 1

Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,880

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.

F2 · price: The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.